I acknowledge the kind remarks by Dr. Loscocco regarding my interpretation \[[@CR1]\] of a recent paper \[[@CR2]\] in which the use of both immunosuppressive therapy and the JAK2 inhibitor for hypercytokinemia due to severe COVID-19 has been proposed. I should have stated that "a recent report by Mehta et al. \[[@CR2]\] in which all patients with severe COVID-19 should be assessed for secondary hemophagocytic lymphohistiocytosis (sHLH) in the bone marrow and hyperferritinemia using the HScore", because it is now evident that severe COVID-19 can cause sHLH \[[@CR3], [@CR4]\]. However, it should be considered that as implied by Dr. Loscocco and in recent reports \[[@CR3], [@CR5]\], patients with severe COVID-19 may not be in a good enough condition to undertake a bone marrow examination due to their severe condition, thus resulting in difficulty demonstrating hemophagocytosis. Regardless of whether hemophagocytosis is demonstrated or whether the HScore should be used, COVID-19 infection can induce hypercytokinemia associated with marked macrophage activation \[[@CR6], [@CR7]\], thus leading to both organ damage and coagulopathy. I would like to reiterate the potential efficacy of low-dose etoposide monotherapy for patients with severe COVID-19 by compensating for the immunoregulator aberration and macrophage activation.
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